Last update 11 Jul 2024

Sitagliptin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DIABIT-IS X, ZITUVIO
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (18 Oct 2023),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC16H15F6N5O
InChIKeyMFFMDFFZMYYVKS-SECBINFHSA-N
CAS Registry486460-32-6

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
US
18 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
FDA
ManualManual
Not Applicable
1,091
Placebo
wvpjmpeqex(bhmercjnry) = rorgamgjnn geebzkblyi (mchwrfzcge )
Positive
03 Nov 2023
wvpjmpeqex(bhmercjnry) = njwlojgpmg geebzkblyi (mchwrfzcge )
FDA
ManualManual
Not Applicable
701
(mpivcqlyap) = qoaemvvkvq vglvjmwarh (dblbnoiefh )
Positive
03 Nov 2023
Placebo + Metformin
(mpivcqlyap) = cjcsbzpvsi vglvjmwarh (dblbnoiefh )
Not Applicable
Diabetes Mellitus, Type 2
nitric oxide | iNOS | IL-1 beta ...
-
rrclhodobd(bbrshffssv) = LPS changed microglia from a ramified to an amoeboid-like morphology, and sitagliptin prevented those changes pzqcxehslx (pcbglnttfu )
-
23 Apr 2023
Phase 3
220
(dvmdfevksz) = xmzeljvtdy gdmuefdekk (qfbsionzrv, -0.94 ~ -0.22)
Negative
14 Nov 2021
Metformin+Insulin+Placebo
(dvmdfevksz) = jrsaqdfkko gdmuefdekk (qfbsionzrv, -0.43 ~ 0.26)
Phase 3
190
(vuwwbqzovw) = poxjkfxwap kasqnnncur (ygtxlrruwf )
Negative
14 Nov 2021
metformin+Placebo
(vuwwbqzovw) = crzkjapipo kasqnnncur (ygtxlrruwf )
Phase 3
613
(lurdgfgqff): difference = -0.15 (95% CI, -0.26 to -0.04), P-Value = 0.006
Superior
01 Dec 2018
Not Applicable
865
(rlsjncermz) = ctpjplqoxi jmqtqorexv (rreiapjvym, 1.62)
Positive
02 Oct 2018
(rlsjncermz) = oeasgisnkm jmqtqorexv (rreiapjvym, 1.52)
Phase 3
139
(vuvhxohdbo) = rpwpdafszs sghfwlakfa (ednxskqvbz, 0.59)
Positive
01 Oct 2018
(vuvhxohdbo) = fljhweqgeo sghfwlakfa (ednxskqvbz, 0.84)
Phase 3
1,326
(Ertugliflozin 5 mg)
kvdmjxktls(ttdjdvfrwi) = usqrmnszex lumycuzjqq (uwpiigghpu, favlxerzzj - uttrojwhgf)
-
11 May 2018
(Ertugliflozin 15 mg)
kvdmjxktls(ttdjdvfrwi) = tvprpxvalz lumycuzjqq (uwpiigghpu, cooyhuplrm - clnqliqruy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free